bluebird bio (bluebird bio) Total Assets : $613.61 Mil (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is bluebird bio Total Assets?

bluebird bio's Total Assets for the quarter that ended in Sep. 2023 was $613.61 Mil.

During the past 12 months, bluebird bio's average Total Assets Growth Rate was 15.50% per year. During the past 3 years, the average Total Assets Growth Rate was -15.50% per year. During the past 5 years, the average Total Assets Growth Rate was -13.50% per year. During the past 10 years, the average Total Assets Growth Rate was 51.30% per year.

During the past 12 years, bluebird bio's highest 3-Year average Total Assets Growth Rate was 494.00%. The lowest was -30.00%. And the median was 21.70%.

Total Assets is connected with ROA %. bluebird bio's annualized ROA % for the quarter that ended in Sep. 2023 was -44.94%. Total Assets is also linked to Revenue through Asset Turnover. bluebird bio's Asset Turnover for the quarter that ended in Sep. 2023 was 0.02.

bluebird bio Total Assets Historical Data

The historical data trend for bluebird bio's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bluebird bio Total Assets Chart

bluebird bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Assets

Get a 7-Day Free Trial

2,242.84

1,727.42

1,781.25

593.80

554.90

bluebird bio Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Assets	Get a 7-Day Free Trial															520.10	554.90	692.74	663.39	613.61

bluebird bio Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

bluebird bio's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	196.343	+	358.559
	=	554.90

bluebird bio's Total Assets for the quarter that ended in Sep. 2023 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2023 )	+	Total Liabilities (Q: Sep. 2023 )
	=	222.536	+	391.072
	=	613.61

bluebird bio (NAS:BLUE) Total Assets Explanation

Total Assets is connected with ROA %.

bluebird bio's annualized ROA % for the quarter that ended in Sep. 2023 is

ROA %	=	Net Income (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	-286.924	/	( (663.393	+	613.608)	/ 2 )
	=	-286.924	/	638.5005
	=	-44.94 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

bluebird bio's Asset Turnover for the quarter that ended in Sep. 2023 is

	Asset Turnover
=	Revenue (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
=	12.392	/	( (663.393	+	613.608)	/ 2 )
=	12.392	/	638.5005
=	0.02

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

bluebird bio Total Assets Related Terms

Thank you for viewing the detailed overview of bluebird bio's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

bluebird bio (bluebird bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » bluebird bio Inc (NAS:BLUE) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

BLUE:Mexico

Address

455 Grand Union Boulevard, Somerville, MA, USA, 02145

Website

https://www.bluebirdbio.com

bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.

Executives

Richard A Colvin	officer: Chief Medical Officer	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Andrew Obenshain	officer: President of SGD	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Christopher Krawtschuk	officer: Chief Financial Officer	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Thomas J Klima	officer: Chief Commercial Officer, SGD	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Richard A. Paulson	director	85 WELLS AVENUE, NEWTON MA 02459
Nick Leschly	director, officer: President and CEO	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joseph Vittiglio	officer: Chief Business & Legal Officer	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Elisabeth Leiderman	director	1325 BOYLSTON STREET, SUITE 500, BOSTON MA 02215
Jason Cole	officer: SVP, Secy. & General Counsel	C/O BLUEBIRD BIO, INC, 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Anne-virginie Eggimann	officer: Chief Regulatory Officer	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Charlotte Jones-burton	director	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Gina Consylman	officer: Chief Financial Officer	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jessica Whitten	officer: Chief Accounting Officer	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Sarah Js Glickman	director	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Najoh Tita-reid	director	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145